Skip to main content

Immunicum Appoints Lotta Ferm as Chief Financial Officer

Press Release

26 October 2021

Immunicum Appoints Lotta Ferm as Chief Financial Officer

Immunicum AB (publ; IMMU.ST) today announced the appointment of Lotta Ferm as Chief Financial Officer (CFO) effective as of November 1, 2021. Lotta Ferm has been acting as Immunicum’s interim CFO since February of this year and will continue to lead the Company’s finance and HR activities.

“Since her appointment as interim CFO, Lotta has been responsible for synergizing the finance, administrative and HR organization following the merger with DCprime, to ensure the smooth integration of both companies in an effective way,” said Erik Manting, Ph.D., Chief Executive Officer of Immunicum. “Lotta’s extensive experience in finance and controlling will continue to play an important role for Immunicum and we are excited to have her as a permanent member of the leadership team.”

“With multiple upcoming value drivers for the Company’s lead programs, I look forward to continue advancing Immunicum’s financial and business objectives that will support the establishment of a leading cell-based immunotherapy platform with the potential to change the standard of care for cancer patients,” added Lotta Ferm, Immunicum’s Chief Financial Officer.

Lotta Ferm served as Immunicum’s interim CFO since February 1, 2021. She brings to Immunicum nearly 30 years of finance and controlling experience. Prior to joining Immunicum, Lotta held senior management positions at Doktor24 Healthcare AB and Medivir AB in the healthcare and life science sectors. In addition, she has held CFO, Head of Finance and Head of Controlling positions leading a range of corporate finance accounting functions. She holds degrees in Business Administration and Economics from Kristianstad University and Växjö University in Sweden.

FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
Telephone: +31 713 322 627
E-mail: ir@immunicum.com

INVESTOR RELATIONS
Kristina Windrup Olander
Spikinc AB
Telephone: +46 72 545 34 74
E-mail: ir@immunicum.com

MEDIA RELATIONS
Sophia Hergenhan & Jacob Verghese
Trophic Communications
Telephone: +49 89 2388 7731
E-mail: immu@trophic.eu

 

ABOUT IMMUNICUM AB (PUBL)
Immunicum is a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm.
www.immunicum.com

 

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.